Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

Blood (2025) 146 (Supplement 1): 643.

https://doi.org/10.1182/blood-2025-643

Published: 2025

Journal Articles

Impact of G-CSF in AML patients treated with venetoclax and azacitidine: A dataml registry study

Blood (2025) 146 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2025-3445

Published: 2025

Journal Articles

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Blood (2025) 146 (Supplement 1): 881.

https://doi.org/10.1182/blood-2025-881

Published: 2025

Journal Articles

Outcome after relapse in older patients with Philadelphia Chromosome–Negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A graall study

Blood (2025) 146 (Supplement 1): 3340.

https://doi.org/10.1182/blood-2025-3340

Published: 2025

Journal Articles

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

Blood (2025) 146 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2025-1744

Published: 2025

Journal Articles

Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a dataml registry study.

Christian Recher, Emilie Bérard, Suzanne Tavitian, Thibaut Leguay, Anne Huynh, Edouard Forcade, Alban Canali, Emilie Klein, Audrey Bidet, Eric Delabesse, Véronique De Mas, Audrey Sarry, Madeline Mougenot, Anne Charlotte De Grande, Arnaud Pigneux, Sarah Bertoli, Pierre-Yves Dumas

Blood (2025) 146 (Supplement 1): 450.

https://doi.org/10.1182/blood-2025-450

Published: 2025

Journal Articles

Randomized comparison of ponatinib versus imatinib in combination with chemotherapy in patients 55 years of age and older with newly diagnosed ph+ ALL: Molecular response and initial outcome analysis of the EWALL PH03 Study

Oliver Ottmann, Tongtong Shi, Kimmo Porkka, Anna Lübking, Emmanuelle Clappier, Yosr Hicheri, Thibaut Leguay, Emilie Lemasle, Sarah Burns, Charlotte Letterme, Catharine Porter, Mia Sydenham, Ian Thomas, Jean-Michel Cayuela, Philippe Rousselot

Blood (2025) 146 (Supplement 1): 440.

https://doi.org/10.1182/blood-2025-440

Published: 2025

Journal Articles

High prognostic value of NGS-based measurable residual FLT3-ITD in AML patients positive for FLT3-ITD treated with ponatinib in combination with cytarabine in first complete remission.

Blood (2025) 146 (Supplement 1): 5295.

https://doi.org/10.1182/blood-2025-5295

Published: 2025

Journal Articles

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Blood (2025) 146 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2025-1682

Published: 2025

Journal Articles

Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Blood (2025) 146 (Supplement 1): 43.

https://doi.org/10.1182/blood-2025-43

Published: 2025

Journal Articles

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Sara K. Silbert, Alexander W. Rankin, Chloe N. Hoang, Alexandra Semchenkova, Regina M. Myers, Elena Zerkalenkova, Hao-Wei Wang, Alexandra E. Kovach, Constance M. Yuan, Dana Delgado Colon, Loïc Vasseur, Alex Bataller, Samuel John, Kaylyn Utley Lyons, Barbara Friedes, Anna Alonso-Saladrigues, Hisham Abdel-Azim, Estelle Balducci, Ahmed Assim Aljudi, Marie Balsat, D. Nathan Biery, Aghiad Chamdin, Bill H. Chang, Raymund S. Cuevo, Barbara De Moerloose, David S. Dickens, Ulrich Duffner, Nicolas Duployez, Firas El Chaer, Michelle Ann Elliott, Gabriele Escherich, Sneha Fernandes, Mandi R. Fitzjohn, Zhubin Gahvari, Stephan A. Grupp, Rui Rochelle He, Cynthia Harrison, Christopher B. Hergott, Emily M. Hsieh, Annette S. Kim, Dennis J. Kuo, Daniel P. Larson, Benjamin J. Lee, Thibaut Leguay, R. Coleman Lindsley, Abhishek A. Mangaonkar, Kerstin Mezger, Holly L. Pacenta, Jing Pan, Marlie Provost, Latika Puri, Sunil S. Raikar, Armando Martinez, Isabella Bristol, Kyle Murphy, Lauren Reiman, Michele Redell, Kelly Reed, Gabrielle Roth-Guepin, Jeremy Rubinstein, Süreyya Savaşan, Kristian Schafernak, Alexandra Stevens, Aimee Talleur, Naomi Torres Carapia, Jacques Vargaftig, Anant Vatsayan, Matthias Wölfl, Liping Zhao, Susana Rives, Vanessa A. Fabrizio, Koji Sasaki, Ibrahim Aldoss, Nicolas Boissel, Susan R. Rheingold, Kara L. Davis, Sara Ghorashian, Elad Jacoby, Alexander Popov, Adam J. Lamble, Nirali N. Shah

Blood (2025) 146 (4): 437–455.

https://doi.org/10.1182/blood.2024026655

Published: 2025

Includes: Supplemental data

Journal Articles

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Blood (2024) 144 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2024-199110

Published: 2024

Journal Articles

Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Pierre-Yves Dumas, Sarah Bertoli, Clémence Santana, Mael Heiblig, Thibaut Leguay, Suzanne Tavitian, Eric Delabesse, Émilie Klein, Emmanuelle Tavernier, Martin Carre, Gaspar Aspas Requena, Anne Banos, Norbert Vey, Arnaud Pigneux, Christian Récher, Sylvain Garciaz

Blood (2024) 144 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2024-210596

Published: 2024

Journal Articles

Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission

Blood (2024) 144 (Supplement 1): 2905.

https://doi.org/10.1182/blood-2024-209998

Published: 2024

Journal Articles

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Blood (2024) 144 (Supplement 1): 731.

https://doi.org/10.1182/blood-2024-198614

Published: 2024

Journal Articles

Genetic alterations and MRD refine risk assessment for KMT2A -rearranged B-cell precursor ALL in adults: a GRAALL study

Blood (2023) 142 (21): 1806–1817.

https://doi.org/10.1182/blood.2023021501

Published: 2023

Includes: Supplemental data

Journal Articles

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Blood (2023) 142 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2023-173379

Published: 2023

Journal Articles

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Blood (2023) 142 (Supplement 1): 518.

https://doi.org/10.1182/blood-2023-179192

Published: 2023

Journal Articles

Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-Study of the Graall-2014/B Trial

Blood (2023) 142 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2023-177847

Published: 2023

Journal Articles

Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry

Jules Higué, Pierre-Yves Dumas, Laetitia Largeaud, Audrey Bidet, Émilie Klein, Olivier Mansier, Lucie Rigolot, Eric Delabesse, Anne Banos, Suzanne Tavitian, Thibaut Leguay, Sarah Guenounou, Edouard Forcade, Sarah Bertoli, Arnaud Pigneux, Christian Recher

Blood (2023) 142 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2023-180773

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

Impact of G-CSF in AML patients treated with venetoclax and azacitidine: A dataml registry study

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Outcome after relapse in older patients with Philadelphia Chromosome–Negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A graall study

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a dataml registry study.

Randomized comparison of ponatinib versus imatinib in combination with chemotherapy in patients 55 years of age and older with newly diagnosed ph+ ALL: Molecular response and initial outcome analysis of the EWALL PH03 Study

High prognostic value of NGS-based measurable residual FLT3-ITD in AML patients positive for FLT3-ITD treated with ponatinib in combination with cytarabine in first complete remission.

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Genetic alterations and MRD refine risk assessment for KMT2A -rearranged B-cell precursor ALL in adults: a GRAALL study

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-Study of the Graall-2014/B Trial

Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only